Entero Therapeutics

Country

Ownership: -

Employees: 9

Market Cap: -

Website

Introduction: First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm involves in therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD,FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.

Clinical Trials

Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis

Phase 2

Completed

Conditions: Cystic Fibrosis
Exocrine Pancreatic Insufficiency

Interventions: Drug: adrulipase

First Posted Date: 2023-02-08

Last Posted Date: 2024-04-11

Lead Sponsor: Entero Therapeutics

Target Recruit Count: 13

Registration Number: NCT05719311

Locations: 🇺🇸
The Cystic Fibrosis Institute, Northfield, Illinois, United States
🇺🇸
Central Florida Pulmonary Group, Orlando, Florida, United States
🇺🇸
Childrens Lung Specialists, Las Vegas, Nevada, United States

Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection

Phase 2

Terminated

Conditions: Covid19

Interventions: Drug: Placebo
Drug: Niclosamide

First Posted Date: 2021-04-26

Last Posted Date: 2024-10-08

Lead Sponsor: Entero Therapeutics

Target Recruit Count: 166

Registration Number: NCT04858425

Locations: 🇮🇳
Yashoda Hospital, Secunderabad, Andhra Pradesh, India
🇮🇳
SSG Hospital and Medical Institute, Vadodara, Gujarat, India
🇺🇦
Municipal Non-profit Enterprise "City Clinical Hospital # 4" of Dnipro City Council, Dnipro, Ukraine

and more 22 locations

Study of Latiglutenase in T1D/CD Patients

Phase 2

Terminated

Conditions: Celiac Disease

Interventions: Drug: Latiglutenase
Drug: Placebo

First Posted Date: 2021-04-09

Last Posted Date: 2024-08-05

Lead Sponsor: Entero Therapeutics

Target Recruit Count: 13

Registration Number: NCT04839575

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States

Niclosamide in COVID-19

Phase 2

Withdrawn

Conditions: Covid19

Interventions: Drug: Placebo
Drug: Niclosamide Oral Tablet

First Posted Date: 2020-09-09

Last Posted Date: 2022-02-21

Lead Sponsor: Entero Therapeutics

Registration Number: NCT04542434

Niclosamide In Moderate COVID-19

Phase 2

Withdrawn

Conditions: COVID

Interventions: Drug: Niclosamide Oral Tablet
Drug: Placebo

First Posted Date: 2020-06-18

Last Posted Date: 2022-02-21

Lead Sponsor: Entero Therapeutics

Registration Number: NCT04436458

OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis

Phase 2

Completed

Conditions: Exocrine Pancreatic Insufficiency (EPI)
Cystic Fibrosis (CF)

Interventions: Drug: MS1819
Drug: Porcine PERT

First Posted Date: 2020-05-06

Last Posted Date: 2022-09-13

Lead Sponsor: Entero Therapeutics

Target Recruit Count: 27

Registration Number: NCT04375878

Locations: 🇺🇸
Investigator Site 102, Altamonte Springs, Florida, United States
🇺🇸
Investigator Site 111, Wichita, Kansas, United States
🇺🇸
Investigator Site 106, Hershey, Pennsylvania, United States

and more 12 locations

Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients

Phase 2

Terminated

Conditions: Celiac Disease

Interventions: Drug: Latiglutenase
Other: Placebo

First Posted Date: 2020-01-28

Last Posted Date: 2024-08-05

Lead Sponsor: Entero Therapeutics

Target Recruit Count: 83

Registration Number: NCT04243551

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Phase 2

Completed

Conditions: Exocrine Pancreatic Insufficiency (EPI)
Cystic Fibrosis (CF)

Interventions: Drug: MS1819
Drug: Porcine PERT

First Posted Date: 2018-11-19

Last Posted Date: 2022-06-06

Lead Sponsor: Entero Therapeutics

Target Recruit Count: 41

Registration Number: NCT03746483

Locations: 🇺🇸
Investigator Site 105, Long Beach, California, United States
🇺🇸
Investigator Site 102, Altamonte Springs, Florida, United States
🇺🇸
Investigator Site 108, Portland, Maine, United States

and more 11 locations